Nakarai H, Chandler P J, Kano K, Morton D L, Irie R F
Division of Surgical Oncology, Armand Hammer Laboratories, Jonsson Comprehensive Cancer Center, University of California, School of Medicine, Los Angeles.
Int Arch Allergy Appl Immunol. 1990;91(3):323-8. doi: 10.1159/000235135.
Hanganutziu-Deicher (H-D) antigen is classified as a heterophile antigen and chemically defined as a glycoconjugate which contains N-glycolylneuraminic acid. H-D antigens are absent from normal human tissues, but can be expressed on a variety of human malignant cells, including melanoma. Natural anti-H-D antibodies have been detected in man with and without malignancies, but in this study when the level of antibody was compared between healthy adults and patients with melanoma, elevated anti-H-D antibody levels were found more frequently in melanoma patients for both IgM (p = 0.0001) and IgG (p = 0.0001). The present study was designed to evaluate the significance of the H-D antigen-antibody system in melanoma suppression. Sera from melanoma patients containing anti-H-D antibody reacted strongly to H-D antigen expressed on melanoma by means of flow cytometry. In a complement-dependent cytotoxicity assay this antibody killed melanoma cells in vitro. In vivo significance of the antibody was assessed by evaluating the relationship between the antibody levels and the clinical course in patients with stage II melanoma. Antibody levels were measured by enzyme-linked immunosorbent assay using a H-D glycoprotein antigen isolated from bovine erythrocytes. A significantly higher level of IgG (p = 0.0640) and IgM (p = 0.0644) anti-H-D antibody was demonstrated in those patients who were free of disease more than 5 years after surgery than in those who relapsed within 2 years. This study provides a rational basis for immunotherapy targeting H-D antigen in human melanoma.
汉加努齐乌-戴歇尔（H-D）抗原被归类为嗜异性抗原，化学上定义为一种含有N-羟乙酰神经氨酸的糖缀合物。正常人体组织中不存在H-D抗原，但可在包括黑色素瘤在内的多种人类恶性细胞上表达。在有或没有恶性肿瘤的人群中均检测到天然抗H-D抗体，但在本研究中，当比较健康成年人与黑色素瘤患者的抗体水平时，发现黑色素瘤患者中IgM（p = 0.0001）和IgG（p = 0.0001）的抗H-D抗体水平升高更为频繁。本研究旨在评估H-D抗原-抗体系统在黑色素瘤抑制中的意义。通过流式细胞术，含有抗H-D抗体的黑色素瘤患者血清与黑色素瘤上表达的H-D抗原发生强烈反应。在补体依赖性细胞毒性试验中，该抗体在体外杀死黑色素瘤细胞。通过评估II期黑色素瘤患者抗体水平与临床病程之间的关系，评估了该抗体在体内的意义。使用从牛红细胞中分离的H-D糖蛋白抗原，通过酶联免疫吸附测定法测量抗体水平。术后无病超过5年的患者中，IgG（p = 0.0640）和IgM（p = 0.0644）抗H-D抗体水平显著高于术后2年内复发的患者。本研究为针对人类黑色素瘤中H-D抗原的免疫治疗提供了合理依据。
